Business Context and Reporting Period
This Form 6-K/A filing by GlaxoSmithKline plc (GSK) covers the period ending January 2015. The document serves as a notification of transactions involving directors and persons discharging managerial responsibilities, specifically detailing changes in share interests for Dr. P J T Vallance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to director share transaction disclosures and does not contain financial performance data.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The only changes disclosed relate to the shareholding of a connected person of a Person Discharging Managerial Responsibility.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports on the acquisition of shares via dividend reinvestment.
Important Facts for Investors
- Transaction Type: Acquisition of GSK Ordinary Shares by Dr. S Dexter, a connected person of Dr. P J T Vallance (Person Discharging Managerial Responsibility).
- Transaction Details:
- 175 shares acquired at 1414.135 pence per share following the dividend reinvestment on October 2, 2014.
- 274 shares acquired at 1417.542 pence per share following the dividend reinvestment on January 8, 2015.
- Reporting Date: The company was advised of these transactions on January 28, 2015.
- Financial Data: No financial metrics are included in this specific filing.